Curated dataset · n=61 verified deals · Not live market data · Scores are descriptive, not forecasts.
You are here

Deals — Network graph, deal flow, valuation matrix, and acquirer landscape.

Flatiron Health
→
Roche

Acquisition · Cash · ROG · announced Jan 8, 2018

View in network
  1. Announced

    Jan 8, 2018

  2. Closed

    Apr 6, 2018

Economics

Cash()

Pre-deal · pre-deal mark: 2018, year precision · rounding grid ±$100M · Roche press release — Flatiron Health acquisition, 2018

~$1.9B fully diluted, subject to adjustments

Target

Flatiron Health

Precision Medicine · Care delivery

HQ New York, NY · Founded 2012

Oncology-specific EHR and real-world evidence platform — 265+ community cancer clinics, data includes breast and ovarian cancer outcomes

  • Roche media release (Apr 6, 2018)
  • Flatiron Health company website
  • Crunchbase - crunchbase.com/organization/flatiron-health

Acquirer

Roche (ROG)

Precision Medicine

HQ Basel, Switzerland

Why this buyer

Curated copy from the verified dataset — not an 8-K LLM summary

Oncology-specific EHR and real-world evidence — data from 265+ clinics enables precision medicine research including breast and ovarian cancer treatment outcomes

Evidence ladder

Single-sourceValue disclosed
  1. Tertiary (trade / analyst)

    Roche media release (Apr 6, 2018)

Limitations

  • Single-source or weak corroboration — treat valuation and timing as directional.
  • ~$1.9B fully diluted, subject to adjustments
  • Pre-deal valuation sourced from: Roche press release — Flatiron Health acquisition, 2018. Pre-deal market-cap and funding citations do not corroborate the acquisition.

Valuation peers · Precision Medicine

Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer, until you sort.

Why included
Foundation MedicineRocheJun 19, 2018same acquirer
Genomic HealthExact SciencesJul 29, 2019value band

Same-sector adjacency — not valuation peers

These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.

Vs this deal
Varian Medical SystemsSiemens HealthineersAug 2, 2020
GRAILIlluminaSep 21, 2020

Other verified deals by Roche

Acquirer program history not already listed as a valuation peer or adjacency row.

No further verified deals

Other verified transactions by Roche are already listed above, or none are in the dataset.

Patient empowerment context

Empowerment context — Flatiron Health

Curated survey mapping

HLTH/Outcomes4Me 2022 surveyed breast cancer patients (n=1,828). Breast cancer care continuum (HLTH 2022). Rows below are analyst-curated mappings to cited survey items — not live patient outcomes for this target.

  • Presented with clinical trial as treatment option (Company / product site)1 in 5cited HLTH 2022Mapping source →
  • No survivorship care plan after active treatment (Company / product site)54%cited HLTH 2022Mapping source →
  • Not aware of survivorship resources (Company / product site)2 in 3cited HLTH 2022Mapping source →

Other curated mappings on these gaps: Biotheranostics, Genomic Health, Foundation Medicine, Focal Therapeutics

Full cited gap matrix →

Related verified workspaces

Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.

Curated verified dataset v11 · updated 2026-10-19 · 1 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.